10th DDR Inhibitors Summit 2027

The 10th DDR Inhibitors Summit 2027 advances research and collaboration in DNA damage response (DDR) inhibition, highlighting emerging biomarkers, novel therapeutic targets, and combination strategies to enhance cancer treatment efficacy and overcome resistance.

Key Topics

• Emerging DDR targets and therapeutic strategies
• Integration of biomarkers to guide drug development
• AI-driven and model-informed drug discovery
• PARP, ATR, and DNA-PK inhibition in cancer therapy
• Combination approaches with radiotherapy and chemotherapy
• Novel modalities including oncolytic viruses and ADCs
• Mechanism-driven innovations in preclinical and clinical studies
• Industry-academia collaborations and funding strategies

Who should Attend

• Oncology researchers
• Clinical scientists and translational medicine experts
• Biotech and pharmaceutical professionals
• Drug discovery and development specialists
• Biomarker and genomics researchers
• Investors and industry leaders in cancer therapeutics